Search clinical trials for: Nafamostat Mesilate

Total 1380 results

Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Shen Lei

Not yet recruiting

Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI

Sepsis

China
Chong Kun Dang Pharmaceutical

Completed

A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

COVID-19

Korea, Republic of
Kyungpook National University Hospital

Completed

Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

Acute Kidney Injury
Xu Li
LanZhou University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University... and other collaborators

Not yet recruiting

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy (NMSICRCT)

Sepsis | Sepsis-induced Coagulopathy | Nafamostat Mesilate
Ensysce Biosciences
National Institute on Drug Abuse (NIDA)

Completed

Oral Nafamostat in Healthy Volunteers

Pharmacokinetics

United States
Chong Kun Dang Pharmaceutical

Completed

A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

COVID-19

Russian Federation
Institut Pasteur de Dakar
Ministry of Health, Senegal; Fann Hospital, Senegal; Diamniadio Children Hospital... and other collaborators

Unknown

Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)

COVID-19

Senegal
Gyeongsang National University Hospital

Unknown

Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia

COVID-19 | Corona Virus Infection
Yonsei University
SK Chemicals Co., Ltd.

Completed

The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy

Acute Kidney Injury

Korea, Republic of
Wonju Severance Christian Hospital

Enrolling by invitation

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study (Nafamostat)

Bleeding | Dialysis; Complications

Korea, Republic of
Talphera, Inc

Not yet recruiting

Nafamostat Efficacy in Phase 3 Registrational CRRT Study (NEPHRO)

Acute Kidney Injury
University of Edinburgh
University of Oxford; Latus Therapeutics; Scottish National Blood Transfusion...

Recruiting

DEFINE - Evaluating Therapies for COVID-19 (DEFINE)

COVID-19

United Kingdom
University Hospital Padova
University of Zurich; Yokohama City University

Recruiting

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) (RACONA)

COVID19

Italy
University of Bologna

Completed

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

Italy
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Refractory Desmoplastic Small Round Cell Tumors

Italy
Xiaobo Yang, MD

Recruiting

Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

Critical Illness | Anticoagulation

China
Xiaotong Hou

Not yet recruiting

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Extracorporeal Membrane Oxygenation Complication

China
University of Melbourne
The George Institute; The University of Queensland; The Peter Doherty Institute... and other collaborators

Recruiting

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT ADAPT)

SARS-CoV-2 Infection (COVID-19)

Australia
Ensysce Biosciences
National Institute on Drug Abuse (NIDA); Quotient Sciences

Completed

Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (MPAR-101)

Pharmacokinetics

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Phase I Study of Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Yale University

Completed

Camostat Mesylate in COVID-19 Outpatients

COVID-19

United States
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom
Merz Pharmaceuticals GmbH

Completed

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Healthy

Germany
Nanjing First Hospital, Nanjing Medical University

Enrolling by invitation

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Main Heading (Descriptor) Terms

China
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Seoul National University Hospital
SK Chemicals Co., Ltd.

Unknown

Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)

Acute Kidney Injury

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Eisai Co., Ltd.

Completed

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Soft Tissue Sarcoma

Japan
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus (EASE)

Subjective Tinnitus

Germany, Portugal, Spain, United Kingdom, Austria
Eisai Inc.

Completed

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Cancer

Netherlands
Hunan Cancer Hospital

Completed

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Metastatic Breast Cancer

China
Oncologia Medica dell'Ospedale Fatebenefratelli
Mario Negri Institute for Pharmacological Research

Completed

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Metastatic Breast Cancer | Toxicity | Neurotoxicity | Adverse Drug Event | Drug Toxicity

Italy

Search clinical trials for: Nafamostat Mesilate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations